# OnCo record paper-schmid-pakt-capivasertib-tnbc-jco-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-schmid-pakt-capivasertib-tnbc-jco-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-schmid-pakt-capivasertib-tnbc-jco-2020" ;
  schema:name "Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial"@en ;
  schema:description "Adding capivasertib to first-line paclitaxel improved survival in metastatic triple-negative cancer from 12.6 to 19.1 months, with the largest gain in the fifth of patients whose tumours carried a PIK3CA, AKT1 or PTEN alteration."@en ;
  schema:url <https://onco.cc/key-papers/paper-schmid-pakt-capivasertib-tnbc-jco-2020/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.19.00368>, <https://pubmed.ncbi.nlm.nih.gov/31841354/> ;
  schema:sameAs <https://doi.org/10.1200/JCO.19.00368> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "Schmid P, Abraham J, Chan S, et al." ;
  onco:related <https://onco.cc/biomarkers/pik3ca-hotspot-mutation/>, <https://onco.cc/biomarkers/akt1-e17k/>, <https://onco.cc/biomarkers/pten-alteration/> ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-metastatic/> ;
  onco:targets <https://onco.cc/targets/akt/>, <https://onco.cc/targets/pik3ca/>, <https://onco.cc/targets/pten/> ;
  onco:drugs <https://onco.cc/drugs/capivasertib/>, <https://onco.cc/drugs/paclitaxel/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:pathways <https://onco.cc/pathways/pi3k-akt-mtor/> ;
  onco:people <https://onco.cc/people/peter-schmid/> ;
  onco:journals <https://onco.cc/journals/jco/> .